Skip to main content

Advertisement

Table 1 Regular Study Procedures

From: Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response

Baseline assessments Month 0Month 6, 12, 18, 24, 30 and 36 after treatment initiation
• Demographic information (date of birth, gender) 
• Determination and documentation of eligibility by the Investigator or authorized representative (according to eligibility criteria) 
• Relevant medical history: e.g., lumbar puncture, MRI, medication history and current medications, medical conditions/surgical history, clinical episode history 
• Physical examination and documentation of vital signs• Physical examination and documentation of vital signs
• Adverse events and concomitant medication• Adverse events and concomitant medication
• MSFC• MSFC
• EDSS• EDSS
• Collection of peripheral blood and serum for several in vitro and ex vivo assessments (8 × 9 ml EDTA blood, 2 × 9 ml serum) as part of the routine blood assessments (including complete blood count, serum creatinine levels, tests of thyroid function)• Collection of peripheral blood and serum for several in vitro and ex vivo assessments (8 × 9 ml EDTA blood, 2 × 9 ml serum) as part of the routine blood assessments (including complete blood count, serum creatinine levels, tests of thyroid function)